Effect of Th17 and Treg Axis Disorder on Outcomes of Pulmonary Arterial Hypertension in Connective Tissue Diseases

Table 1

Baseline clinical characteristics of study cohort.

Variable	CTD ()	CTD-aPAH			value′	value′′
		Total ()	Mild to moderate ()	Severe ()
Gender
Female (%)	81.2% (95)	79.2% (42)	77.3% (17)	80.6% (25)	0.766	0.765
Age (years)					0.058	0.921
BMI (kg/m^2)					0.155	0.738
FEV1%					0.01	0.030
DLCO%					0.01	0.037
mPAP (mmHg)					0.01	0.032
sPAP (mmHg)					0.01	0.009
PCWP (mmHg)	—				—	0.385
CI (L/min/m^2)					0.01	0.005
6MWD (m)					0.01	0.041
WHO functional class
I (%)	76.1% (89)	35.8% (19)	54.5% (12)	22.6% (7)	0.01	0.017
II-III (%)	23.9% (28)	64.2% (34)	45.5% (10)	77.4% (24)	0.01	0.017
Raynaud's phenomenon (%)	41.0% (48)	58.5% (31)	40.9% (9)	71.0% (22)	0.034	0.029
Cause of CTD
SS	29	31	12	19
SLE	42	6	2	4
MCTD	22	13	4	9
RA	21	1	0	1
pSS	3	2	1	1

value′: CTD versus total CTD-aPAH; value′′: mild to moderate CTD-aPAH versus severe CTD-aPAH. Data were presented as mean ± SD, (%).
CTD: connective tissue diseases; CTD-aPAH: connective tissue diseases-associated pulmonary arterial hypertension; BMI: body mass index; FEV1%: forced expiratory lung volume in 1s (% predicted); DL_CO%: carbon monoxide diffusion capacity (% predicted); mPAP: mean pulmonary artery pressure; sPAP: systolic pulmonary artery pressure; PCWP: pulmonary capillary wedge pressure; CI: cardiac index; 6MWD: 6-minute walk test distance; SS: systemic sclerosis; SLE: systemic lupus erythematosus; MCTD: mixed connective tissue disease; RA: rheumatoid arthritis; pSS: primary Sjogren’s syndrome.